AURA
NASDAQ · Biotechnology
Aura Biosciences Inc
$6.44
-0.15 (-2.28%)
Open$6.73
Previous Close$6.59
Day High$6.73
Day Low$6.43
52W High$9.54
52W Low$4.73
Volume—
Avg Volume689.2K
Market Cap686.53M
P/E Ratio—
EPS$-1.76
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+404.0% upside
Current
$6.44
$6.44
Target
$32.46
$32.46
$26.53
$32.46 avg
$55.40
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 444.35M | 423.64M | 422.21M |
| Net Income | 17.80M | 13.08M | 16.40M |
| Profit Margin | 4.0% | 3.1% | 3.9% |
| EBITDA | 20.20M | 21.97M | 19.97M |
| Free Cash Flow | 12.95M | 9.01M | 11.94M |
| Rev Growth | +9.8% | +0.1% | +6.7% |
| Debt/Equity | 1.09 | 1.02 | 0.95 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |